Online Database of Chemicals from Around the World Search | Submit | Advertise

Home >> Chemical Listing >> Afuresertib>> Market Analysis Reports
 

Market Analysis Reports of Afuresertib

Therapeutic Class Overview: Treating Refractory Hematological Malignancies
Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ...

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ...

Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022
... liposomal Paxalisib Tucidinostat Capivasertib Miransertib Afuresertib Enzastaurin CU 05 API-2 Pravitinib Uprosertib ALM ...




Copyright ©  chemBlink. All rights reserved. Content Disclaimer | about chemBlink | Contact